等待开盘 11-16 09:30:00 美东时间
-0.212
-20.15%
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **1. 财务业绩:** SeaStar Medical公布2026财年第三季度(截至2026年9月30日)财务业绩: - **净营收(Net Revenue)**:约63.5万美元,主要来自QUELIMMUNE疗法需求增长。 - **毛利率(Gross Profit Margin)**:超过90%,与本财年前几个季度保持一致。 - **前九个月净营收**:约170万美元。 - **运营费用(Operating Expenses)**:520万美元。其中研发费用(R&D)因NEUTRALIZE-AKI临床试验活动、SCD开发费用及人员成本增加而上升;
11-12 12:23
SeaStar Medical Holding (NASDAQ:ICU) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www....
11-12 06:19
FDA has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled post-approval study requirements, allowing broader access for critically ill children with life-threatening AKI. Results from the registry showed a statistically significant improvement in 90-day survival (65.1% vs. 47.5%) and no device-related adverse events. The therapy, which uses selective cytopheretic device (SCD) technology, targets destructive hyperin...
11-03 13:21
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today new positive data from the late-breaking presentation at ASN Kidney Week 2026 in...
10-23 00:05
New data from ASN Kidney Week 2026 shows QUELIMMUNE (SCD-PED) significantly improves survival in pediatric sepsis-associated AKI. The study demonstrated higher survival rates at Day 90 (65.1% vs. 47.4%) and hospital discharge, with no device-related adverse events. Bayesian and frequentist analyses supported these findings, highlighting the potential benefit of QUELIMMUNE therapy.
10-22 16:01
An announcement from SeaStar Medical Holding ( ($ICU) ) is now available. On Oc...
10-06 04:49
SeaStar Medical Holding Corporation announced that a late-breaking abstract evaluating the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week 2026 meeting in Denver. The presentation, titled "Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (...
10-02 13:43
SeaStar Medical Holding ( ($ICU) ) just unveiled an update. On June 25, 2026, S...
07-02 04:36
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Selective Cytopheretic Device (SCD) therapy has received dedicated ICD-1...
06-23 20:29
今日重点评级关注:HC Wainwright & Co.:维持Autolus Therapeutics"买入"评级,目标价从9美元升至10美元;Maxim Group:维持Rezolute"买入"评级,目标价从4美元升至10美元
05-15 10:49